AR130689A1 - Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos - Google Patents
Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estosInfo
- Publication number
- AR130689A1 AR130689A1 ARP230102666A ARP230102666A AR130689A1 AR 130689 A1 AR130689 A1 AR 130689A1 AR P230102666 A ARP230102666 A AR P230102666A AR P230102666 A ARP230102666 A AR P230102666A AR 130689 A1 AR130689 A1 AR 130689A1
- Authority
- AR
- Argentina
- Prior art keywords
- proteins
- anchored
- heterocyclic
- inhibitors
- mutant kras
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación proporciona compuestos que tienen actividad inhibitoria sobre las proteínas KRAS G12C mutante, composiciones farmacéuticas, que comprenden los compuestos, y métodos para tratar determinados trastornos, como el cáncer, incluidos, a mero título enunciativo, cáncer de pulmón, cáncer de páncreas y cáncer colorrectal. En particular, la divulgación proporciona compuestos de formula (2), y sales farmacéuticamente aceptables de estos, donde los sustituyentes son como se los describe.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263413548P | 2022-10-05 | 2022-10-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130689A1 true AR130689A1 (es) | 2025-01-08 |
Family
ID=88920846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102666A AR130689A1 (es) | 2022-10-05 | 2023-10-05 | Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP4598916A1 (es) |
| JP (2) | JP2025533831A (es) |
| AR (1) | AR130689A1 (es) |
| AU (2) | AU2023356612A1 (es) |
| MX (2) | MX2025004108A (es) |
| TW (1) | TW202423440A (es) |
| UY (1) | UY40474A (es) |
| WO (2) | WO2024076670A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024212035A1 (en) | 2023-01-26 | 2025-08-14 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025076288A1 (en) | 2023-10-06 | 2025-04-10 | Amgen Inc. | Combination therapy for cancer treatment |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021002804A (es) * | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| GB202001344D0 (en) * | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| JP2024509280A (ja) * | 2021-03-10 | 2024-02-29 | ベータ・ファーマ・インコーポレイテッド | Ｋｒａｓ阻害物質としてのピリドピリミジン誘導体 |
-
2023
- 2023-10-05 UY UY0001040474A patent/UY40474A/es unknown
- 2023-10-05 AU AU2023356612A patent/AU2023356612A1/en active Pending
- 2023-10-05 TW TW112138313A patent/TW202423440A/zh unknown
- 2023-10-05 WO PCT/US2023/034533 patent/WO2024076670A2/en not_active Ceased
- 2023-10-05 EP EP23810457.4A patent/EP4598916A1/en active Pending
- 2023-10-05 WO PCT/US2023/034535 patent/WO2024076672A1/en not_active Ceased
- 2023-10-05 JP JP2025519562A patent/JP2025533831A/ja active Pending
- 2023-10-05 AR ARP230102666A patent/AR130689A1/es unknown
- 2023-10-05 EP EP23810189.3A patent/EP4598915A2/en active Pending
- 2023-10-05 JP JP2025519572A patent/JP2025535046A/ja active Pending
- 2023-10-05 AU AU2023356610A patent/AU2023356610A1/en active Pending
-
2025
- 2025-04-04 MX MX2025004108A patent/MX2025004108A/es unknown
- 2025-04-04 MX MX2025004107A patent/MX2025004107A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025535046A (ja) | 2025-10-22 |
| AU2023356612A1 (en) | 2025-04-03 |
| TW202423440A (zh) | 2024-06-16 |
| JP2025533831A (ja) | 2025-10-09 |
| EP4598915A2 (en) | 2025-08-13 |
| MX2025004108A (es) | 2025-06-02 |
| WO2024076672A1 (en) | 2024-04-11 |
| AU2023356610A1 (en) | 2025-04-03 |
| EP4598916A1 (en) | 2025-08-13 |
| MX2025004107A (es) | 2025-07-01 |
| UY40474A (es) | 2024-04-15 |
| WO2024076670A2 (en) | 2024-04-11 |
| WO2024076670A3 (en) | 2024-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130689A1 (es) | Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos | |
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| MX2022000854A (es) | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. | |
| SA523440916B1 (ar) | Prmt5 مشتقات كربوكساميد ثلاثية الحلقة كمثبطات | |
| CO2022016377A2 (es) | Inhibidores de kras tricíclicos fusionados | |
| CR20240451A (es) | Compuestos de modulación de kras g12d | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| ECSP22083926A (es) | Compuestos útiles para inhibir la quinasa ret | |
| MX2021009276A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2. | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| AR130425A1 (es) | Inhibidores de kras(g12d) | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| UY39517A (es) | Inhibidores de la btk | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| UY26564A1 (es) | Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos | |
| CL2025000087A1 (es) | Compuestos inhibidores de tirosina quinasa 2 y uso. | |
| AR132890A1 (es) | Aminas bicíclicas como inhibidores de cdk2 | |
| AR131414A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso | |
| AR131413A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso | |
| AR131001A1 (es) | Inhibidores de la proteína tirosina fosfatasa, composiciones y métodos de uso | |
| CO2023017151A2 (es) | Inhibidores de ripk1 de nicotinamida | |
| AR126755A1 (es) | Compuestos heterocíclicos y métodos de uso | |
| MX2024000022A (es) | Compuestos terapeuticos. | |
| EA201992005A1 (ru) | Арильные, гетероарильные и гетероциклические фармацевтические соединения для лечения медицинских нарушений | |
| ECSP024374A (es) | Derivados del 4,5-dihidro-tiazol-2-ylamina y sus usos como inhibidores de no sintetasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |